Please login to the form below
Alnylam takes off on APOLLO trial results
Provides first late-stage evidence on the biotech's gene-silencing platform
UCB’s antiepileptic drug gains new US indication
FDA approves Briviact as a monotherapy to treat POS
With US approval, GSK now needs rapid uptake for COPD triple
Aims to quickly launch the predicted blockbuster to revive its R&D portfolio
NICE says OK to Opdivo for lung cancer via CDF
Comes after BMS drops the price of its PD-1 inhibitor
MSD's Keytruda wins new bladder cancer indication in Europe
Will treat locally advanced or mUC patients
AbbVie and Roche plan Venclexta combo filings in leukaemia
MURANO trial shows the duo’s treatment extends PFS
Teva offloads women's health unit in quickfire deals
The Israeli pharma group is also set to sell its oncology and pain business
CHMP backs maintenance therapy for Tesaro's Zejula
Swiss biotech's PARP inhibitor recommended for approval in ovarian cancer
Forming a picture of health
As life expectancy increases how can stakeholders ensure the last decades of life are healthy ones?
-
SMC gives green light for Amgen’s KyprolisThe committee also gives verdict on three other products
-
Healthcare in the digital ageProf Jan Kimpen on a decade of digital change in healthcare and its future direction of travel
-
Bayer bags speedy US approval for lymphoma drug AliqopaFDA decision sets the pharma firm up for a showdown with Gilead's Zydelig
-
Amgen's Mvasi is first FDA-approved cancer biosimilarOffers prospect of lower-cost alternative to Roche's Avastin
-
Sandoz says Humira biosimilar clears clinical hurdleIts drug matches the safety and efficacy of AbbVie’s plaque psoriasis blockbuster
-
GSK's Shingrix sails through FDA advisory committeeShingles vaccine data proved safe and effective, says the panel
-
Roche faces prospect of second Rituxan biosimilar in USFDA begins its review of Sandoz's version of the immunotherapy treatment
-
GSK preps COPD filing for asthma pioneer NucalaMoves despite reporting mixed data for the treatment earlier this year
-
Lilly's abemaciclib data leaves potential uncertainMONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali
Latest appointments
-
Teva's Mark Salyer joins AmarinTakes up newly-created chief commercial officer role
-
M3 appoints Simon Walker as director of educationIn his new role he will lead the company's educational strategy
-
Ljubisav Matejevic joins health IT firm Ascom
He is appointed to central and eastern Europe role
-
Neovii Pharmaceuticals promotes Juergen Pohle to CEOHe will take over from Alexandre Sudarskis in January
-
Cancer Research UK's Karen Vousden to join BMS board
She will also serve on the pharma firm's Science and Technology Committee
Featured jobs
-
Medical Writer
-
Competitive Salary
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
-
Account Director
-
Salary TBC
- Junior - Mid Level Medical Copywriter, Healthcare Advertising Ag...
-
£30-35, 000 according to skills and experience
-
Programme Director
-
Salary TBC
Subscribe to our email news alerts
- Novartis looks outside pharma for digital transformation
- Merck to co-lead new oncology big data alliance
- GSK closes in on EU approval for triple COPD therapy
- Amgen's Mvasi is first FDA-approved cancer biosimilar
- Teva offloads women's health unit in quickfire deals
- Customer experience rules the digital age
PMHub
Page & Page
Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...
Latest intelligence
- OUTiCO Case Study - Product Launch
- POSITIVE FORMULARY SUCCESS WITHIN 8 MONTHS!...
- An insight into Multi-Channel Account Management
- At OUTiCO we often talk about moving away from traditional methods, embracing change, and offering an exceptional outsourcing service, but what does that mean day to day?...
- Why AI might be the rep’s best friend
- When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...
Quick links
Infographics
